BCAX financial statements
The full income statement, balance sheet, and cash-flow statement for Bicara Therapeutics Inc. (BCAX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| 156M+88.9% | 82.4M+106.5% | 39.9M | ||
| Research & development | — | 63.6M+107.8% | 30.6M | |
| Selling, general & administrative | 30.5M+62.5% | 18.8M+102.4% | 9.27M | |
| General & administrative | 30.5M+62.5% | 18.8M+102.4% | 9.27M | |
| Operating income | -156M-88.9% | -82.4M-106.5% | -39.9M | |
| Interest & investment income | 17.9M+22.6% | 14.6M+1009.7% | 1.31M | |
| Other non-operating income | 17.9M+22.6% | 14.6M+220.6% | -12.1M | |
| Pre-tax income | -138M-103.1% | -67.8M-30.5% | -52.0M | |
| Income tax | 217K+16.0% | 187K+3640.0% | 5.00K | |
| Net income | -138M-102.9% | -68.0M-30.8% | -52.0M | |
| -$2.52+37.8% | -$4.05+95.5% | -$89.61 | ||
| EPS (basic) | -$2.52+37.8% | -$4.05+95.5% | -$89.61 | |
| Weighted-avg shares (basic) | 54.7B+225.4% | 16.8B+2797.0% | 580M | |
| Weighted-avg shares (diluted) | 54.7B+225.4% | 16.8B+2797.0% | 580M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| 422M-16.0% | 503M+117.5% | 231M | ||
| Cash & equivalents | 96.7M-80.3% | 490M+112.5% | 230M | |
| Short-term investments | 318M | 0.00 | — | |
| Cash & short-term investments | 415M | — | — | |
| Prepaid expenses | 7.25M-43.4% | 12.8M+1925.6% | 633K | |
| 431M-15.5% | 510M+118.0% | 234M | ||
| Property, plant & equipment | 330K+112.9% | 155K-23.3% | 202K | |
| Operating lease right-of-use | 1.70M+146.5% | 690K+12.6% | 613K | |
| Long-term investments | — | 0.00 | — | |
| Other non-current assets | 6.91M+4.4% | 6.62M+216.0% | 2.09M | |
| 28.9M+60.9% | 18.0M+19.3% | 15.1M | ||
| Accrued liabilities | — | 12.9M+59.9% | 8.05M | |
| Current lease liability | 1.12M+84.0% | 607K+113.0% | 285K | |
| 29.5M+63.0% | 18.1M+17.1% | 15.5M | ||
| Non-current lease liability | 593K+352.7% | 131K-64.8% | 372K | |
| Operating lease liability (total) | 1.71M+131.7% | 738K | — | |
| Other non-current liabilities | — | 0.00-100.0% | 17.0K | |
| 401M-18.4% | 492M+430.6% | -149M | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | |
| Common stock | 7.00K+0.0% | 7.00K+250.0% | 2.00K | |
| Additional paid-in capital | 760M+6.6% | 713M+16673.7% | 4.25M | |
| Retained earnings | -359M-62.4% | -221M-44.4% | -153M | |
| Accumulated other comprehensive income | 243K | 0.00 | — | |
| Total liabilities & equity | 431M-15.5% | 510M+118.0% | 234M | |
| Common shares issued | 56.6M+4.0% | 54.4M+7547.8% | 712K | |
| Common shares outstanding | 56.6M+4.0% | 54.4M+8401.1% | 640K | |
| Shares outstanding (cover) | 65.5M+20.1% | 54.5M | — | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| -107M-42.9% | -74.8M-63.8% | -45.6M | ||
| Depreciation & amortization | 105K+87.5% | 56.0K+194.7% | 19.0K | |
| Share-based compensation | 15.0M+102.9% | 7.40M+289.5% | 1.90M | |
| Deferred income taxes | 0.00 | 0.00 | 0.00 | |
| -318M-3538266.7% | -9.00K+98.5% | -586K | ||
| Capital expenditure | 280K+294.4% | 71.0K-87.9% | 586K | |
| Free cash flow | -107M-43.2% | -74.8M-61.9% | -46.2M | |
| Acquisitions | 0.00 | 0.00 | 0.00 | |
| Purchases of investments | 318M | 0.00 | — | |
| Proceeds from sale of PP&E | 0.00-100.0% | 62.0K | 0.00 | |
| 32.3M-90.3% | 334M+22.6% | 272M | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 29.5M-91.1% | 332M | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | |
| Net change in cash | -393M-251.6% | 259M+14.6% | 226M | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| Market cap | 1.10B+16.0% | 950M | — | |
| P/B | 2.7×+42.1% | 1.9× | — | |
| Source filing | 10-K | 10-K | 10-K |
About this data
Source: BCAX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all BCAX filings on SEC EDGAR → Not investment advice.